Merck is benchmarking performance in 2009 that will help us set targets and metrics in future years. We are particularly focused on achieving World Health Organization (WHO) pre-qualification for our products, and increasing the number of countries who use our products in their government access programs. These results can only be achieved through having the highest quality products and an expanded dialogue with customers about how these products can help meet their needs. These metrics will guide our actions and indicate our success as we strive to integrate our research and policy agenda, pricing strategy and supply chain management to maximize the public health impact of our products.
Access to Medicines and Vaccines Performance Data Summary 2005-2008
| Global |
2008 |
2007 |
2006 |
2005 |
| Number of Merck products for which not-for-profit prices are offered to least developed countries |
6 |
6 |
2 |
2 |
| Number of patients on Merck ARV therapy—all formulations, all products (percentage in the developing world) |
653,867 [76] |
763,118 [91] |
701,391 [93] |
N/D |
| Number of countries and territories in which patients are on at least one formulation of Merck's ARVs |
131 |
135 |
125 |
N/D |
Product donations ($US)
(percentage in the developing world)*† |
766M [77] |
766M [79] |
768M [58] |
979M [45] |
N/D: No data available because we did not track the information in this way before 2006.
* We value our product donations based on the U.S. wholesale price. Decrease in product donations is due in large part to decline in patient enrollment in our corporate U.S. Patient Assistance Program attributed in part to an increasing number of patients with prescription drug coverage (including through the Medicare Prescription Drug Program, which began in January 1, 2006).
† Includes MMOP (including ACHAP), MDP and Merck U.S. Patient Assistance Program
In 2005, donations of Merck medicines and vaccines through Merck Medical Outreach Program (MMOP) and MECTIZAN Donation Program (MDP) totaled $437 million. This included $383 million worth of MECTIZAN® (ivermectin).
In 2006, donations of Merck medicines and vaccines through MMOP and MDP totaled $442 million. This included $396 million worth of MECTIZAN.
In 2007, donations of Merck medicines and vaccines through MMOP and MDP totaled $605 million. This included $480 million worth of MECTIZAN.
In 2008, donations of Merck medicines and vaccines through MMOP and MDP totaled $592 million. This included $549 million worth of MECTIZAN.
The content on this page was last modified on September 15, 2009.
Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.
Printer Friendly Page
PDF* 451KB)